Genes and Diseases (Jul 2024)
Genotyping on circulating tumor DNA improves mutation detection rate in high-risk diffuse large B-cell lymphoma
- Yi Xia,
- Li Wang,
- Jinhua Liang,
- Haorui Shen,
- Jiazhu Wu,
- Hua Yin,
- Yue Li,
- Huayuan Zhu,
- Jianyong Li,
- Wei Xu
Affiliations
- Yi Xia
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- Li Wang
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- Jinhua Liang
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- Haorui Shen
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- Jiazhu Wu
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- Hua Yin
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- Yue Li
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- Huayuan Zhu
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- Jianyong Li
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- Wei Xu
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China; Corresponding author. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China.
- Journal volume & issue
-
Vol. 11,
no. 4
p. 101116
